.  i  n  f  o 
Novartis AG News
 Login   Help  
 About   News 
 Indices 2019 
 Market News 
 Company News 
 All Time Highs 
 Trading Systems 
company details RSS feed
 Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors 2011-09-05 
 Novartis International BioCamp spotlights how diversity spurs innovation across the company and inspires future science leaders 2011-08-29 
 FDA requests additional clinical data on Novartis drug ACZ885 for the treatment of gouty arthritis 2011-08-29 
 Novartis drug Afinitor® recommended by CHMP for EU approval to treat patients with advanced pancreatic neuroendocrine tumors 2011-07-22 
 Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19 
 Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers for 2011-2012 influenza season 2011-07-15 
 Phase III trial of Novartis drug Afinitor® met primary endpoint of reducing SEGA tumor size in patients with tuberous sclerosis 2011-07-08 
 Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need 2011-07-05 
 Novartis receives FDA approval for Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary disease 2011-07-01 
 Novartis receives approval in Japan for Onbrez® Inhalation Capsules, a novel once-daily bronchodilator therapy for patients with COPD 2011-07-01 
 Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD 2011-06-30 
 Novartis drug Votubia® recommended by CHMP for approval in the EU for children and adults with SEGA associated with tuberous sclerosis 2011-06-24 
 FDA panel endorses efficacy but not safety of Novartis drug ACZ885 for gouty arthritis; did not support approval in proposed indication 2011-06-22 
 Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia 2011-06-16 
 Novartis application for expanded Menveo® indication from 2 months of age accepted for review by FDA 2011-06-16 
 Novartis candidate vaccine Bexsero® shows significant potential in providing broad coverage against meningococcal serogroup B infections 2011-06-09 
 Novartis gains European Commission approval for Lucentis® to treat vision loss due to macular edema secondary to RVO 2011-06-06 
 Novartis drug Glivec® shows significant overall survival benefit for patients with GIST after three years of adjuvant treatment vs. one year 2011-06-05 
 Novartis JAK inhibitor INC424 shows significant clinical benefit for myelofibrosis patients in two Phase III studies at ASCO 2011-06-04 
 Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2011-06-01 
 Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid 2011-05-25 
 Alcon wins Patanol® US patent infringement lawsuit against Apotex 2011-05-24 
 Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly 2011-05-19 
 Novartis provides restated consolidated income statement data for 2010 and Q1 2011 following the merger with Alcon; no change to total reported Group data 2011-05-18 
 Novartis studies show Onbrez® Breezhaler® plus tiotropium is more effective than tiotropium alone in treatment of COPD 2011-05-15 
 Novartis drug Votubia® approved as first medication in Switzerland for SEGA, a benign brain tumor associated with tuberous sclerosis 2011-05-11 
 Novartis gains FDA approval for Afinitor® as first new treatment in nearly three decades for patients with advanced pancreatic NET 2011-05-06 
 New analysis representing largest available dataset highlights relative safety of Lucentis® (ranibizumab) compared to unlicensed intravitreal Avastin® (bevacizumab) 2011-05-04 
 Novartis receives EU approval for Rasilamlo®, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2011-04-28 
 Novartis makes strong start for the year 2011-04-19 
 Novartis drug Afinitor® recommended by FDA oncology advisory committee for approval to treat advanced NET of pancreatic origin 2011-04-12 
 Novartis discontinues clinical trial of Tasigna® for investigational use in newly diagnosed patients with unresectable and/or metastatic GIST 2011-04-11 
 Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows 2011-04-11 
 Novartis amends current US FDA application for Afinitor® to seek indication for advanced neuroendocrine tumors of pancreatic origin 2011-04-08 
 Novartis completes merger with Alcon 2011-04-08 
 Novartis shareholders approve merger of Alcon into Novartis 2011-04-08 
 Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis 2011-04-07 
 Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows 2011-03-31 
 FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD 2011-03-23 
 Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China 2011-03-22 
Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice.